GAMMA Investing LLC Acquires 7,388 Shares of Omeros Corporation (NASDAQ:OMER)

GAMMA Investing LLC lifted its position in Omeros Corporation (NASDAQ:OMER) by 14,486.3% during the 1st quarter, according to the company in its most recent filing with the SEC. The fund owned 7,439 shares of the biopharmaceutical company’s stock after purchasing an additional 7,388 shares during the quarter. GAMMA Investing LLC’s holdings in Omeros were worth $61,000 at the end of the most recent reporting period.

Several other large investors have also made changes to their positions in the company. Truvestments Capital LLC grew its holdings in Omeros by 116.5% during the 4th quarter. Truvestments Capital LLC now owns 3,102 shares of the biopharmaceutical company’s stock worth $31,000 after acquiring an additional 1,669 shares during the last quarter. Tower Research Capital LLC TRC raised its holdings in Omeros by 79.0% during the 4th quarter. Tower Research Capital LLC TRC now owns 4,467 shares of the biopharmaceutical company’s stock worth $44,000 after buying an additional 1,972 shares during the period. Quantbot Technologies LP bought a new position in shares of Omeros during the 4th quarter worth approximately $46,000. Picton Mahoney Asset Management grew its stake in shares of Omeros by 692.5% during the 4th quarter. Picton Mahoney Asset Management now owns 5,040 shares of the biopharmaceutical company’s stock worth $50,000 after acquiring an additional 4,404 shares in the last quarter. Finally, US Bancorp DE bought a new position in shares of Omeros during the 4th quarter worth approximately $81,000. Institutional investors own 48.79% of the company’s stock.

Analysts Set New Price Targets

OMER has been the subject of several analyst reports. HC Wainwright started coverage on shares of Omeros in a research note on Tuesday, June 10th. They issued a “buy” rating and a $9.00 target price for the company. Wall Street Zen downgraded Omeros from a “hold” rating to a “sell” rating in a report on Friday, June 6th. D. Boral Capital reissued a “buy” rating and set a $36.00 target price on shares of Omeros in a report on Tuesday, May 13th. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Omeros in a research note on Friday, May 16th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, Omeros presently has an average rating of “Moderate Buy” and an average target price of $18.00.

Omeros Trading Up 3.6%

NASDAQ:OMER opened at $3.50 on Thursday. The stock has a market cap of $205.07 million, a P/E ratio of -1.32 and a beta of 2.20. The stock’s 50-day moving average is $4.59 and its 200-day moving average is $7.28. Omeros Corporation has a 1-year low of $2.97 and a 1-year high of $13.60.

Omeros (NASDAQ:OMER) last released its quarterly earnings results on Thursday, May 15th. The biopharmaceutical company reported ($0.65) earnings per share for the quarter, missing the consensus estimate of ($0.60) by ($0.05). As a group, equities analysts forecast that Omeros Corporation will post -3.09 EPS for the current year.

Omeros Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.